

Major shareholders and management demonstrate their faith in CombiGene by participating in the warrants of series TO4 and TO5

November 16 to November 30, 2020, is the subscription period for CombiGene's warrants in series TO4 and TO5. Both major shareholders and board members and former board members have informed the company that they intend to subscribe for shares in CombiGene.

Participation in series TO4

CombiGene's largest owner Ivar Nordqvist has announced his intention to exercise his series TO4 warrants. Peter Nilsson (board member of CombiGene), Arne Ferstad (former Chairman of the Board) and Jan Nilsson (CEO and board member of CombiGene) have all informed the company that they intend to exercise all of their warrants.

Participation in series TO5

Series TO5 was created in connection with the directed issue to NYIP (Nyenburgh Holding BV) carried out in August 2020. TO5 has the same terms and conditions as the series TO4 warrants. NYIP, a leading Dutch life-science investor, has informed CombiGene of its intention to fully subscribe for the TO5 series.



"It is very gratifying that major shareholders such as Ivar Nordqvist and NYIP have informed us that they intend to participate in subscription series TO4 and TO5 respectively. It means a lot financially and creates additional energy in the company. Similarly, it is very encouraging that Peter Nilsson of CombiGene's Board

of Directors and CombiGene's former Chairman Arne Ferstad are also participating in the TO4 series," says CombiGene CEO Jan Nilsson in a comment.

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

For further information:

CombiGene AB (publ)
Jan Nilsson, CEO
Tel: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the board
Tel: +46(0) 70 777 22 09
bert.junno@combigene.com

Please read *INGENIEIOUS*, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. *INGENIEIOUS* and press releases are available at www.combigene.com